Clinical Significance of OX40 and OX40 Ligand in the Peripheral Blood of Patients with Myasthenia Gravis

Figure 1

OX40/OX40L expression on the peripheral blood lymphocytes and plasma of patients with MG at baseline. (a) Representative expression of OX40 on CD4⁺ T cells and OX40L on CD19⁺ B cells and CD14⁺ mononuclear cells in the patients with MG at baseline and HC groups. The red lines indicate specific staining results measured by flow cytometry, and the blue lines indicate isotype controls. (b) Comparison of OX40 expression on CD4⁺ T cells in the patients with MG at baseline and HC groups. (c) Comparison of OX40L expression on CD19⁺ B cells in the patients with MG at baseline and HC groups. (d) Comparison of OX40L expression on CD14⁺ mononuclear cells in the patients with MG at baseline and HC groups. (e) Comparison of sOX40L plasma levels in the patients with MG at baseline and HC groups. (f) Comparison of sOX40L plasma levels in the patients with MG at baseline and HC groups.

(a)

(b)

(c)

(d)

(e)

(f)